Quarterly ResultJul 9, 2026, 08:31 PM
Mesoblast Ryoncil® Net Revenue $36M Q4, $115M FY26
AI Summary
Mesoblast Limited announced preliminary Ryoncil® net revenue of US$36 million for the quarter and US$115 million for the full year ended June 30, 2026. The company's CEO, Dr. Silviu Itescu, expressed satisfaction with the strong uptake and revenues exceeding initial projections. Mesoblast anticipates continued revenue growth in the upcoming fiscal year, supported by a strong capital position and well-funded operations.
Key Highlights
- Ryoncil® net revenue for the quarter ended June 30, 2026, was US$36 million.
- Ryoncil® net revenue for the full year ended June 30, 2026, was US$115 million.
- Revenues have exceeded initial projections since launch.
- Company anticipates continued revenue growth in the coming fiscal year.
- Mesoblast reports a strong capital position with operations well-funded through revenue growth.
- Ryoncil® is the first FDA-approved mesenchymal stromal cell (MSC) product for any indication.
Price Impact
More from MESO